Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.52 |
| ▸ | MTOR | P42345 | 7/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472120 | 1.00 | PRMT5 (0.52) | PRMT5MTORERN1FGFR1FLT1 | |
| SCHEMBL24140809 | 0.82 | MTOR (0.51) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL30472234 | 0.82 | MTOR (0.51) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL24141173 | 0.82 | ALDH1A1 (0.54) | FGFR1AMY1A | |
| SCHEMBL24140520 | 0.80 | ERN1 (0.48) | MTORERN1AMY1ATLR8TLR7 | |
| SCHEMBL30472077 | 0.80 | ERN1 (0.48) | MTORERN1AMY1ATLR8TLR7 | |
| SCHEMBL24141207 | 0.78 | MTOR (0.48) | MTORERN1SMPD3 | |
| SCHEMBL24141205 | 0.76 | CLK2 (0.47) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL24141208 | 0.73 | FYN (0.46) | MTORERN1 | |
| SCHEMBL30472078 | 0.72 | ERN1 (0.44) | MTORERN1TLR8TLR7SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | PRMT5 3718/4885MTOR 3934/4885ERN1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.